Trials / Conditions / Primary Mediastinal B-cell Lymphoma

Primary Mediastinal B-cell Lymphoma

13 registered clinical trials studyying Primary Mediastinal B-cell Lymphoma — 3 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Amping up With PemJAK NCT07283822	Seda S. Tolu	Phase 2
Recruiting	Study in Patients With Relapsed/Refractory Primary Mediastinal Lymphoma Treated With Pembrolizumab or Nivoluma NCT06781450	IRCCS Azienda Ospedaliero-Universitaria di Bologna	—
Active Not Recruiting	Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells NCT04911478	Adicet Therapeutics	—
Completed	Immune Responses to COVID-19 Vaccination in Lymphoma Patients NCT04858568	University Hospital Southampton NHS Foundation Trust	—
Terminated	A Phase 1 Study of ADI-001 in B Cell Malignancies NCT04735471	Adicet Therapeutics	Phase 1
Completed	Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL) NCT02669017	ADC Therapeutics S.A.	Phase 1
Completed	Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001) NCT02631044	Juno Therapeutics, a Subsidiary of Celgene	Phase 1
Recruiting	Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL NCT02393157	New York Medical College	Phase 2
Completed	A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013) NCT01953692	Merck Sharp & Dohme LLC	Phase 1
Active Not Recruiting	Randomized, Open-label, Two-arms, Phase III Comparative Study Assessing the Role of Involved Mediastinal Radio NCT01599559	International Extranodal Lymphoma Study Group (IELSG)	N/A
Completed	CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma NCT00924326	National Cancer Institute (NCI)	Phase 1 / Phase 2
Completed	A Clinico-Pathologic Study of Primary Mediastinal B-Cell Lymphoma NCT00944567	International Extranodal Lymphoma Study Group (IELSG)	—
Completed	R-MegaCHOP-ESHAP-BEAM in Patients With High-Risk Aggressive B-Cell Lymphomas NCT00558220	Czech Lymphoma Study Group	Phase 2